Research on TCM Syndrome of Lung Cancer Patients and the Intervention Effect of Shengxuetang Plays during Chemotherapy
- VernacularTitle:肺癌患者化疗期间中医证型及升血汤干预作用研究
- Author:
Qi FU
;
Xiaomin WANG
;
Guowang YANG
- Publication Type:Journal Article
- Keywords:
lung cancer;
chemotherapy;
Shengxuetang;
side & toxic effects;
TCM syndrome
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2006;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the TCM syndrome changes of lung cancer patients before and after chemotherapy and the effect of Shengxuetang on dealing with side and toxic effects caused by chemotherapy and patient’s immune function. Method Phase III and IV lung cancer patients were randomly divided into two groups, treatment group and control group. Patients in the treatment group were given the combination of chemotherapy and Shengxuetang, while those in the control group were given the combination of chemotherapy and berbamine. Peripheral WBC count, HGB level, platelet count, T-cell count, and NK cell activity were measured, and other toxic effects were observed before and after chemotherapy. Results Before chemotherapy, there were two syndrome types, one is the deficiency of Qi and Yin, and the other is phlegm-damp due to deficiency of Qi accompanied with blood stasis. During the treatment, these two syndrome gradually transformed to the deficiency of both Qi and Yin and coagulation of phlegm and blood stasis. The chance for patients to develop myelosuppression had no difference between two groups, however, most patients in the treatment group developed grade I myelosuppression, while in the control group, most patients developed grade II myelosuppression. G-CSF was prescribed more in the control group than in the treatment group (P
